Multiparametric magnetic resonance imaging-ultrasound fusion-guided prostate biopsy: Role in diagnosis and management of prostatic cancer

摘要

We have read with great interest the review article by Sonn et al. [1] in the November 2013 issue of Urologic Oncology. We agree with the article content, but we believe that the role of multiparametric magnetic resonance imaging-ultrasound (mpMRI-US) fusion-guided prostate biopsy, in the various steps of prostate cancer (PCa) diagnosis and management, should be further outlined.The PCa aggressiveness stratification includes 3 groups of different risk: low, intermediate, and high risk. The most common clinical data used to define low-risk PCa include the following: Gleason score < 6 (no disease pattern 4 or 5), prostate-specific antigen (PSA) level < 10 ng/ml, clinical Tl or T2a clinical category disease, PSA kinetics (stable) before diagnosis, PSA density <0.15 ng/ml/cm3, percentage of positive cores at biopsy <33%, and the extent of cancer in any cores <50% [2].